Author

Wen Zhou

EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: FINAL RESULTS FROM THE PHASE 3 U-ACHIEVE MAINTENANCE STUDY
EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: FINAL RESULTS FROM THE PHASE 3 U-ACHIEVE MAINTENANCE STUDY

Wen Zhou  et al.

EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING 16 WEEKS’ EXTENDED INDUCTION TREATMENT FOLLOWED BY 52 WEEKS’ MAINTENANCE TREATMENT IN THE U-ACHIEVE/U-ACCOMPLISH TRIALS
EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING 16 WEEKS’ EXTENDED INDUCTION TREATMENT FOLLOWED BY 52 WEEKS’ MAINTENANCE TREATMENT IN THE U-ACHIEVE/U-ACCOMPLISH TRIALS

Wen Zhou  et al.

PATIENTS WITH ULCERATIVE COLITIS REPORT IMPROVEMENTS IN ABDOMINAL PAIN, BOWEL URGENCY, AND FATIGUE WITH 8-WEEK UPADACITINIB TREATMENT IN TWO PHASE 3 TRIALS: U-ACHIEVE AND U-ACCOMPLISH
PATIENTS WITH ULCERATIVE COLITIS REPORT IMPROVEMENTS IN ABDOMINAL PAIN, BOWEL URGENCY, AND FATIGUE WITH 8-WEEK UPADACITINIB TREATMENT IN TWO PHASE 3 TRIALS: U-ACHIEVE AND U-ACCOMPLISH

Wen Zhou  et al.

IMPACT OF INFLAMMATORY BURDEN ON EFFICACY OF UPADACITINIB MAINTENANCE THERAPY IN ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 U-ACHIEVE STUDY
IMPACT OF INFLAMMATORY BURDEN ON EFFICACY OF UPADACITINIB MAINTENANCE THERAPY IN ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 U-ACHIEVE STUDY

Wen Zhou  et al.

UPADACITINIB TREATMENT IMPROVES HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 INDUCTION STUDIES U-ACHIEVE AND U-ACCOMPLISH
UPADACITINIB TREATMENT IMPROVES HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 INDUCTION STUDIES U-ACHIEVE AND U-ACCOMPLISH

Wen Zhou  et al.

BENEFITS OF HIGH VERSUS LOW DOSE UPADACITINIB AS MAINTENANCE TREATMENT IN ULCERATIVE COLITIS PATIENTS WHO WERE RESPONDERS TO 8-WEEK INDUCTION WITH UPADACITINIB: RESULTS FROM THE U-ACHIEVE PHASE 3 MAINTENANCE TRIAL
BENEFITS OF HIGH VERSUS LOW DOSE UPADACITINIB AS MAINTENANCE TREATMENT IN ULCERATIVE COLITIS PATIENTS WHO WERE RESPONDERS TO 8-WEEK INDUCTION WITH UPADACITINIB: RESULTS FROM THE U-ACHIEVE PHASE 3 MAINTENANCE TRIAL

Wen Zhou  et al.

EFFICACY OF UPADACITINIB DOSE ESCALATION IN A PHASE 3 LONG-TERM EXTENSION ULCERATIVE COLITIS STUDY
EFFICACY OF UPADACITINIB DOSE ESCALATION IN A PHASE 3 LONG-TERM EXTENSION ULCERATIVE COLITIS STUDY

Wen Zhou  et al.

BENEFIT–RISK ASSESSMENT OF UPADACITINIB TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
BENEFIT–RISK ASSESSMENT OF UPADACITINIB TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Wen Zhou  et al.

RAPIDITY OF SYMPTOM CONTROL WITH UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM TWO RANDOMIZED PHASE 3 STUDIES
RAPIDITY OF SYMPTOM CONTROL WITH UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM TWO RANDOMIZED PHASE 3 STUDIES

Wen Zhou  et al.

SYMPTOMS AND LABORATORY VALUES AS PROXIES FOR ENDOSCOPIC AND HISTOLOGIC CLINICAL ENDPOINTS IN ULCERATIVE COLITIS: A MEDIATION ANALYSIS BASED ON UPADACITINIB PHASE 3 INDUCTION TRIALS
SYMPTOMS AND LABORATORY VALUES AS PROXIES FOR ENDOSCOPIC AND HISTOLOGIC CLINICAL ENDPOINTS IN ULCERATIVE COLITIS: A MEDIATION ANALYSIS BASED ON UPADACITINIB PHASE 3 INDUCTION TRIALS

Wen Zhou  et al.

MATCHING-ADJUSTED INDIRECT COMPARISONOF UPADACITINIB VERSUS VEDOLIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
MATCHING-ADJUSTED INDIRECT COMPARISONOF UPADACITINIB VERSUS VEDOLIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Wen Zhou  et al.

Item 1 - 11 / 11
1